Abstract
Recent findings have thrust poly(ADP-ribose) polymerases (PARPs) into the limelight as potential chemotherapeutic targets. To provide a framework for understanding these recent observations, we review what is known about the structures and functions of the family of PARP enzymes, and then outline a series of questions that should be addressed to guide the rational development of PARP inhibitors as anticancer agents.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / therapeutic use
-
Cell Death
-
DNA Damage
-
DNA, Neoplasm / genetics
-
Dacarbazine / analogs & derivatives
-
Dacarbazine / therapeutic use
-
Deoxycytidine / analogs & derivatives
-
Deoxycytidine / therapeutic use
-
Gemcitabine
-
Humans
-
Kinetics
-
Mice
-
Neoplasms / enzymology
-
Neoplasms / pathology
-
Poly (ADP-Ribose) Polymerase-1
-
Poly(ADP-ribose) Polymerase Inhibitors
-
Poly(ADP-ribose) Polymerases / genetics
-
Poly(ADP-ribose) Polymerases / metabolism
-
Poly(ADP-ribose) Polymerases / therapeutic use*
-
Substrate Specificity
-
Temozolomide
Substances
-
Antineoplastic Agents
-
DNA, Neoplasm
-
Poly(ADP-ribose) Polymerase Inhibitors
-
Deoxycytidine
-
Dacarbazine
-
PARP1 protein, human
-
Poly (ADP-Ribose) Polymerase-1
-
Poly(ADP-ribose) Polymerases
-
Temozolomide
-
Gemcitabine